title: OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies.
authors.affiliation: Nephrology Department, Hopital Erasme, Brussels, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Abramowicz
authors.forename: D J
authors.initials: DJ
authors.lastname: Norman
authors.forename: M
authors.initials: M
authors.lastname: Goldman
authors.forename: L
authors.initials: L
authors.lastname: De Pauw
authors.forename: P
authors.initials: P
authors.lastname: Kinnaert
authors.forename: L
authors.initials: L
authors.lastname: Kahana
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
authors.forename: C F
authors.initials: CF
authors.lastname: Shield
authors.forename: A P
authors.initials: AP
authors.lastname: Monaco
authors.forename: J L
authors.initials: JL
authors.lastname: Vanherweghem
mesh_terms: D000206:Actuarial Analysis; D001379:Azathioprine / Q000627:therapeutic use; D001530:Belgium; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology / Q000502:physiology*; D006684:HLA-DR Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007511:Ischemia; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009926:Organ Preservation; D015996:Survival Rate; D014481:United States
chemical_list: D006684:HLA-DR Antigens; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine